Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-241 in Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015Phase 2Recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
A Phase 2 trial of PFL-241 in non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Started Sep 2024; status: recruiting.
02
Drugs
PFL-241
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06567015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567015.